Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04300296 · ClinicalTrials.gov registry record · Phase 2
PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT04300296 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 111 participants.
The verdict
NCT04300296, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
The primary purpose of the proof of concept study is to elucidate the efficacy of secukinumab in the treatment of adult patients with biopsy-proven lichen planus not adequately controlled by topical therapies, and to assess the safety and tolerability over 32 weeks.
Interventions
- OTHER Placebo
- DRUG secukinumab 300 mg Q4W
- DRUG secukinumab 300 mg Q2W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2020-07-27 |
| Est. Completion | 2022-05-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04300296
The ClinicalTrials.gov registry entry for NCT04300296 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04300296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04300296 about?
NCT04300296 is a clinical study titled "PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus". The primary purpose of the proof of concept study is to elucidate the efficacy of secukinumab in the treatment of adult patients with biopsy-proven lichen planus not adequately controlled by topical therapies, and to assess the safety and tolerability over 32 weeks.
What is the current status of trial NCT04300296?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2020-07-27. Estimated completion is 2022-05-03.
What interventions are being tested in trial NCT04300296?
The interventions under investigation include: Placebo (OTHER), secukinumab 300 mg Q4W (DRUG), secukinumab 300 mg Q2W (DRUG).
Who is sponsoring clinical trial NCT04300296?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.